In addition, despite the fact that SGLT-2 inhibitors were shown to significantly decrease pulmonary capillary wedge pressure compared to placebo among subjects with HFrEF [75], demonstrating a significant effect on central hemodynamics, none of the studies performed in the acute HF setting assessed this efficacy outcome. The gene discussed is SLC5A2; the disease is hydrops fetalis.